Publication & Citation Trends
Publications
0 total
The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
Cited by 0
Semantic Scholar
POSTER: CML-641 Efficacy, Safety, and End-of-Treatment Mutational Results in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML): 5-Year Follow-Up of the Phase 2 OPTIC Study
Cited by 0
Semantic Scholar
CML-641: Efficacy, Safety, and End-of-Treatment Mutational Results in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML): 5-Year Follow-Up of the Phase 2 OPTIC Study
Cited by 0
Semantic Scholar
ASC4OPT 96-week results: Asciminib once or twice daily continues to be highly efficacious and demonstrates favorable safety in patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance to two or more tyrosine kinase inhibitors
Cited by 0
Semantic Scholar
The Influence of the COVID-19 Pandemic in NK Cell Subpopulations from CML Patients Enrolled in the Argentina Stop Trial
Cited by 0
Semantic Scholar
Integrating cytokine profiles with clinical and molecular biomarkers to predict molecular relapse after TKI discontinuation in CML patients
Cited by 0
Semantic Scholar
Evaluation of leukemic stem cell (CD26 +) in chronic myeloid leukemia patients with different molecular responses and in treatment-free remission
Cited by 4
Semantic Scholar
Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study
Cited by 0
Semantic Scholar
Research Topics
Chronic Myeloid Leukemia Treatments
(81)
Chronic Lymphocytic Leukemia Research
(73)
Acute Myeloid Leukemia Research
(18)
Acute Lymphoblastic Leukemia research
(18)
Eosinophilic Disorders and Syndromes
(15)
Affiliations
Universidad de Buenos Aires
Centro Ricerche FIAT
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia
Fundación para el Desarrollo de la Ecología
Development Fund